Daniele Spitaleri
Overview
Explore the profile of Daniele Spitaleri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari C, Lo Fermo S, et al.
Neurotherapeutics
. 2025 Feb;
22(2):e00552.
PMID: 39965993
Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated...
2.
Dhondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, et al.
Comput Methods Programs Biomed
. 2025 Feb;
263:108624.
PMID: 39965473
Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as...
3.
Muller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, et al.
CNS Drugs
. 2025 Feb;
39(4):403-416.
PMID: 39953338
Background: In relapsing-remitting multiple sclerosis (RRMS), extended exposure to high-efficacy disease modifying therapy may increase the risk of side effects, compromise treatment adherence, and inflate medical costs. Treatment de-escalation, here...
4.
Yeh W, van der Walt A, Skibina O, Kalincik T, Alroughani R, Kermode A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Oct;
11(6):e200328.
PMID: 39442037
Background And Objectives: Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS...
5.
Kreiter D, Kalincik T, Hupperts R, Patti F, Spitaleri D, Foschi M, et al.
CNS Drugs
. 2024 Sep;
38(11):921-930.
PMID: 39242483
Background: Spinal cord lesions in multiple sclerosis (MS) have considerable impact on disability. High-efficacy disease-modifying treatments (hDMTs) are associated with greater reduction of relapses and new brain lesions compared to...
6.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 Sep;
271(10):7066-7068.
PMID: 39231861
No abstract available.
7.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, et al.
PLOS Digit Health
. 2024 Jul;
3(7):e0000533.
PMID: 39052668
Background: Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the...
8.
Iaffaldano P, Lucisano G, Guerra T, Paolicelli D, Portaccio E, Inglese M, et al.
Ann Clin Transl Neurol
. 2024 Jul;
11(8):2008-2015.
PMID: 38970214
Objective: No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) events are currently available. We aimed to compare...
9.
Lal A, Foong Y, Sanfilippo P, Spelman T, Rath L, Levitz D, et al.
J Neurol
. 2024 Jun;
271(9):5813-5824.
PMID: 38935148
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study...
10.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 May;
271(8):5074-5082.
PMID: 38805052
Objectives: We investigated the occurrence and relative contribution of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) to confirmed disability accrual (CDA) and transition to secondary progression (SP)...